Group 1 - Heritage Commerce Corp announced the appointment of Christopher J. Abate to its Board of Directors, expanding the Board from eight to nine members [1] - Julie Biagini-Komas, Chair of the Board, expressed confidence in Mr. Abate's experience in real estate and finance, highlighting his leadership skills as a valuable addition to the Board [2] - Clay Jones, President & CEO, praised Mr. Abate's extensive experience in complex markets and product innovation, indicating that his collaborative approach will benefit both the Board and shareholders [2] Group 2 - Mr. Abate has over 20 years of experience in the financial services industry, including his role as CEO of Redwood Trust, Inc. since May 2018 [2] - Prior to his current position, Mr. Abate held various roles at Redwood Trust, including President, Chief Financial Officer, and Controller, showcasing a strong background in finance and accounting [2] - Heritage Commerce Corp, established in October 1997, is the parent company of Heritage Bank of Commerce, which has full-service branches across multiple locations in California [3]

Core Viewpoint - Unitil Corporation has successfully closed a public offering of 1,602,358 shares of common stock at a price of $46.65 per share, raising approximately $74.75 million in proceeds before deductions [1][2]. Group 1: Offering Details - The offering included the full exercise of the underwriters' over-allotment option [1]. - The proceeds from the offering will be used for equity capital contributions to regulated utility subsidiaries, repayment of outstanding indebtedness, and general corporate purposes [3]. - Wells Fargo Securities, LLC and Scotia Capital (USA) Inc. acted as active bookrunners for the offering, with Janney Montgomery Scott LLC serving as bookrunner [4]. Group 2: Company Overview - Unitil Corporation is a public utility holding company providing electricity and natural gas in New England, serving approximately 109,400 electric customers and 97,600 natural gas customers [6]. - The company is committed to community service and the development of efficient energy delivery technologies [6].

Financial Performance - Adecoagro S.A. reported an Adjusted EBITDA of $68.1 million for the Sugar, Ethanol & Energy business in 2Q25, which is a decrease of 36.3% year-over-year [3] - The Farming business saw an Adjusted EBITDA of $1.1 million in 2Q25, down $36.7 million year-over-year [6] - Overall, Adjusted EBITDA for the company was down 60.5% in 2Q25 compared to the previous year, primarily due to losses in biological assets and higher costs [9] Sales and Production - Gross sales decreased by 1.4% year-over-year in 2Q25, attributed to lower prices for most products, while accumulated sales increased by 9.9% due to higher volumes sold, especially in ethanol [9] - The company achieved record production in its Rice operations, contributing positively to the Farming business [6] Cost and Pricing - The cost of production for the year-to-date was reported at 9.0 cents per pound, an increase from 7.9 cents per pound in the same period last year [5] - There were year-over-year losses in the mark-to-market of biological assets and agricultural produce due to lower prices [7] Debt Management - Adecoagro issued $500 million in Senior Notes due 2032 with a 7.50% coupon, using proceeds to fund a cash tender offer for its Senior Notes due 2027 [8][10] - The company improved its debt maturity profile and financial flexibility through this transaction [10] Shareholder Distribution - As of the report date, Adecoagro committed $45.2 million to shareholder distributions, including $10.2 million for share repurchases and $35.0 million for cash dividends [11]

Company Overview - Graphjet Technology has developed patented technology to recycle palm kernel shells into single layer graphene and artificial graphite, positioning itself as an innovative producer in the graphene and graphite market [6] Collaboration and Research - Graphjet has agreed to collaborate with the Centre for Materials Engineering and Smart Manufacturing (MERCU) at Universiti Kebangsaan Malaysia (UKM) to utilize graphite and graphene in additive manufacturing technology for advanced heat sinks [1][2] - The collaboration is part of the Consortium of Research Excellence (KKP) 2025 under the Malaysian Ministry of Higher Education [1] Technological Advancements - The completion of a new laboratory enhances Graphjet's capability for quality testing and research on its graphite and graphene products, reducing reliance on third-party testing services and improving turnaround times for development programs [2] - The focus on additive manufacturing technology aims to improve existing heat sinks and develop new advanced heat sinks, particularly for data centers [3] Market Demand - There is a surging demand for specialized chips, especially AI chips, which require more efficient cooling solutions, thus increasing the need for advanced heat sinks [3] - The data center industry is booming in Malaysia and Southeast Asia, with major companies like Amazon Web Services, Microsoft, Google Cloud, Alibaba Cloud, and Equinix & NTT investing in the region [4]

~ Revenues from Ordinary Activities up 470% and Revenues from Contracts with Customers from Continuing Operations up 722% to A$3.8 Million ~ ~ Annual General Meeting to be Held on Tuesday, November 18, 2025 ~ MCDONALD, Tenn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTCQB: AMROF) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value C103, refractory alloy, and titanium powders for additive and advanced manufacturing of components utilized by the defense, space, and avia ...

Core Insights - Resmed has elected Nicole Mowad-Nassar to its board of directors, effective August 15, 2025, while thanking Rich Sulpizio for his two decades of service as he retires from the board [1][5]. Group 1: Board Changes - Nicole Mowad-Nassar is currently the President of Specialty and U.S. Therapeutics Operations at AbbVie, managing a $6 billion commercial portfolio across 17 therapeutic areas and overseeing a workforce of 6,000 [2]. - Rich Sulpizio has served on Resmed's board since 2005, chairing the Compensation Committee and serving on the Audit Committee and Nominating and Governance Committee [5][6]. - Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee, standing for reelection at the 2025 Annual Meeting of Stockholders [4]. Group 2: Professional Background - Mowad-Nassar has over 30 years of experience in strategic, commercial, and operational roles within the pharmaceutical and healthcare sectors, with a focus on digital innovation [7]. - At AbbVie, she played a key role in the commercial integration of the $63 billion Allergan acquisition, ensuring continuity in product launches while minimizing operational disruption [3]. Group 3: Leadership Perspectives - Mick Farrell, Resmed's Chairman and CEO, highlighted Mowad-Nassar's extensive experience and commitment to patient access and digital engagement, indicating her potential to enhance the board's strategic direction [4]. - Farrell expressed gratitude for Sulpizio's contributions, noting his energy and people-first mindset during board discussions [6].

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT" or the “Company”) (Cboe CA:TILT) (OTCID: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, announced today the closing of the sale of two of its Massachusetts dispensaries to In Good Health. The definitive agreement for this transaction was previously announced on February 3, 2025. Simultaneously, with the closing, ...

GARDNER, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit, taking place virtually on Tuesday, August 19, 2025. The webcast will take place at 9:30 a.m. ET on Tuesday, August 19, 2025. The webcast can be ...

Core Insights - Fabrinet reported exceptional financial results for the fourth quarter and fiscal year 2025, achieving record quarterly revenue of $910 million and annual revenue of $3.4 billion, marking a 19% increase year-over-year [2][6][7]. Financial Highlights - Fourth quarter revenue was $909.7 million, up from $753.3 million in the same quarter of fiscal year 2024 [7]. - GAAP net income for the fourth quarter was $87.2 million, compared to $81.1 million in the fourth quarter of fiscal year 2024 [7]. - Non-GAAP net income for the fourth quarter was $95.6 million, compared to $88.0 million in the same quarter of the previous year [7]. - For fiscal year 2025, GAAP net income was $332.5 million, an increase from $296.2 million in fiscal year 2024 [7]. - Non-GAAP net income for fiscal year 2025 was $368.8 million, compared to $324.6 million in fiscal year 2024 [7]. Business Outlook - Fabrinet expects first quarter revenue for fiscal year 2026 to be in the range of $910 million to $950 million [5]. - The company remains optimistic about the growing demand across all areas of its business, anticipating favorable trends to continue into the first quarter and beyond [2][5]. Operational Performance - The company achieved a gross profit of $111.3 million for the fourth quarter, with a gross margin of 12.2% [27]. - Operating income for the fourth quarter was $89.1 million, reflecting an operating margin of 9.8% [28]. - The company reported a non-GAAP operating profit of $97.5 million for the fourth quarter, with a non-GAAP operating margin of 10.7% [28]. Cash Flow and Investments - Net cash provided by operating activities for fiscal year 2025 was $328.4 million, down from $413.1 million in fiscal year 2024 [31]. - Non-GAAP free cash flow for fiscal year 2025 was $207.3 million, compared to $365.6 million in the previous year [31].

Core Viewpoint - Iovance Biotherapeutics has received conditional approval from Health Canada for Amtagvi (lifileucel), marking it as the first T cell therapy for solid tumors and the first treatment option for advanced melanoma after prior therapies [1][2]. Company Overview - Iovance Biotherapeutics focuses on developing novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients and aims to be a leader in this field [5]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve patient outcomes [5]. Product Details - Amtagvi is indicated for adult patients with unresectable or metastatic melanoma who have progressed after at least one prior systemic therapy, including a PD-1 blocking antibody and, if applicable, a BRAF inhibitor [1][2]. - The approval in Canada is based on the results from the global, multicenter C-144-01 trial, which demonstrated safety and efficacy in patients previously treated with anti-PD-1 therapy [2][3]. Clinical Trials - The C-144-01 trial is a Phase 2 study that enrolled patients with metastatic melanoma, establishing efficacy based on objective response rate (ORR) and duration of response (DOR) [3]. - Iovance is also investigating Amtagvi in frontline advanced melanoma through the Phase 3 trial TILVANCE-301 and in additional solid tumor types [4]. Market Strategy - The company plans to authorize its first Canadian treatment center within the next few months and is advancing its strategy for Amtagvi in other international markets [2].